2025
MIF as an oncogenic driver of low‐heterogeneity melanomas
Tran T, Sánchez‐Zuno G, Kulkarni R, Kluger H, Bucala R. MIF as an oncogenic driver of low‐heterogeneity melanomas. Molecular Oncology 2025, 19: 1295-1298. PMID: 40131169, PMCID: PMC12077282, DOI: 10.1002/1878-0261.70031.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorImproving therapeutic outcomesMigration inhibitory factorPotential therapeutic utilityImmune landscapeMelanoma clonesImmune escapeT cellsImmunoregulatory cytokinesTumor heterogeneityTumor progressionOncogenic driversPathway inhibitorTherapeutic outcomesTumor evolutionInhibitory factorCell proliferationMelanomaTumorCellsAntagonistCytokines
2015
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Sausen M, Phallen J, Adleff V, Jones S, Leary R, Barrett M, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban C, Scharpf R, White J, O’Dwyer P, Allen P, Eshleman J, Thompson C, Klimstra D, Linehan D, Maitra A, Hruban R, Diaz L, Von Hoff D, Johansen J, Drebin J, Velculescu V. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature Communications 2015, 6: 7686. PMID: 26154128, PMCID: PMC4634573, DOI: 10.1038/ncomms8686.Peer-Reviewed Original ResearchConceptsGenomic alterationsGenetic predictors of outcomeDetect circulating tumor DNAAssociated with improved survivalTumor-specific mutationsPancreatic cancer patientsLiquid biopsy analysisClinical implicationsPredictors of outcomeWhole-exome analysisDetection of ctDNAPotential therapeutic utilityClinical relapseLocalized diseaseTumor DNAPancreatic adenocarcinomaImproved survivalPancreatic cancerSolid cancersTumor typesBiopsy analysisPoor outcomeCancer patientsSomatic mutationsTumor
2014
Renalase
Guo X, Wang L, Velazquez H, Safirstein R, Desir GV. Renalase. Current Opinion In Nephrology & Hypertension 2014, 23: 513-518. PMID: 24992568, PMCID: PMC4383282, DOI: 10.1097/mnh.0000000000000044.Peer-Reviewed Original ResearchConceptsSingle nucleotide polymorphismsEnzymatic functionType 1 diabetesMitogen-activated protein kinase pathwayNucleotide polymorphismsProtein kinase BProtein kinase pathwayCellular actionsPlasma membraneKinase pathwayKinase BPotential therapeutic utilityCertain single nucleotide polymorphismsEnzymatic propertiesIschemic strokeImmune modulatorsRenalase geneTherapeutic utilityCytoprotective effectsClinical implicationsRenalaseConsistent associationPotential roleDiabetesCytokines
2013
Evaluating Effects of EPO in Rodent Behavioral Assays Related to Depression
Duman C, Newton S. Evaluating Effects of EPO in Rodent Behavioral Assays Related to Depression. Methods In Molecular Biology 2013, 982: 127-140. PMID: 23456866, DOI: 10.1007/978-1-62703-308-4_8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsForced-swim testNeurotrophic actionsNovel object recognition testPotential antidepressant propertiesTreatment of depressionTissue-protective propertiesObject recognition testPotential therapeutic utilityEffect of erythropoietinRodent behavioral modelsAntidepressant propertiesDepressive disorderRodent modelsTherapeutic utilityRodent behavioral assaysNeurotrophic compoundsHyponeophagia testErythropoietinCytokine erythropoietinDepressionImportant regulatorBehavioral assaysProtective propertiesRecognition testAntidepressants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply